Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD (4523)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Eisai : clinches Merck deal to develop and sell cancer drug, shares soar

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2018 | 08:30am CEST
Eisai Co Ltd Representative Corporate Officer and CEO Haruo Naito attends a news conference at the company headquarters in Tokyo

NEW YORK/TOKYO (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses.

The deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck's immunotherapy Keytruda, could be worth up to $5.76 billion (4.14 billion pounds) to Eisai, but most of that would be contingent on eventual sales.

Eisai shares surged 10 percent on the news, with the Japanese drugmaker saying Lenvima may become a blockbuster drug generating annual sales of at least $1 billion in the year ending March 2021.

U.S. drugmaker Merck will be entitled to half of all global Lenvima sales revenue, even for its already approved uses for thyroid cancer and in combination with another drug for kidney cancer.

The deal is similar to a multibillion-dollar oncology collaboration Merck struck with AstraZeneca Plc on its cancer drug Lynparza and another medicine last July.

"Like the Lynparza deal with AstraZeneca, this starts to really broaden out Merck's portfolio," Frank Clyburn, head of Merck's commercial oncology business, said in an interview. "And Merck will start to receive revenue right away."

Under the deal, Eisai will receive an upfront payment of $300 million and up to $650 million for certain option rights through March 2021. Eisai could receive another $385 million in clinical and regulatory milestones, while Merck will receive $450 million as reimbursement for research and development costs.

The collaboration gives Eisai access to Merck's R&D and sales clout as well as a means of maximizing the potential of Lenvima in combination with the leading immunotherapy drug.

Following positive trial data showing that Lenvima with Keytruda led to tumor shrinkage in 63 percent of advanced kidney cancer patients, the combination received breakthrough designation from the U.S. Food and Drug Administration.

The combination also appeared to enhance the impact of Keytruda on advanced kidney cancer.

Breakthrough status is a designation given to treatments demonstrating substantial improvement over existing therapies in treating a serious or life threatening illness.

The companies said they will develop the combination for 11 different potential uses across six other cancer types, including skin cancer and bladder cancer.

"It makes sense ... to try to develop the drug to the full extent possible as monotherapy and in combination with Keytruda," Roger Perlmutter, president of Merck Research Laboratories, said in an interview.

Lenvima, an oral drug known chemically as lenvatinib, was discovered by Eisai scientists and belongs to a class of medicines known as tyrosine kinase inhibitors that block the blood vessel supply to tumors and tumor growth.

The injection of funds following the deal will be used to accelerate research and development of treatments for Alzheimer's disease and cancer, Eisai Chief Executive Haruo Naito told a news conference in Tokyo.

Eisai's shares, currently worth some $17 billion, have been hit in recent months by setbacks for two Alzheimer's drugs in development with Biogen Inc.

One drug, BAN2401, failed to meet the main goal of a mid-stage trial, Biogen said in December. In February, the U.S. drugmaker said it was enrolling more patients for its late-stage trial drug aducanumab, heightening concerns about the challenges of Alzheimer's drug studies.

(Reporting by Bill Berkrot in New York and Sam Nussey in Tokyo; Additional reporting by Chang-Ran Kim, Minami Funakoshi in Tokyo; Editing by Lisa Shumaker and Edwina Gibbs)

By Bill Berkrot and Sam Nussey

Stocks treated in this article : Merck and Company, Eisai Co., Ltd
Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.41% 61.28 Delayed Quote.8.46%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EISAI CO., LTD
04:42aEISAI : AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injectio..
AQ
06/15EISAI : Industry-academia-government joint development agreement concerning nucl..
AQ
06/15EISAI : To establish new research facility 'eisai center for genetics guided dem..
AQ
06/15EISAI : to set up dementia research facility in US
AQ
06/14EISAI : Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerabi..
AQ
06/14EISAI : to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Ma..
AQ
06/14EISAI : Industry-Academia-Government Joint Development Agreement Concerning Nucl..
AQ
06/14EISAI : looking past amyloid, tau with new drug discovery center
AQ
06/14EISAI : to close Andover site, move to new Alzheimers drug discovery center in C..
AQ
06/14EISAI : Industry-Academia-Government Joint Development Agreement Concerning Nucl..
AQ
More news
News from SeekingAlpha
06/18Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold 
06/07This One Study Could Radically Change The Cancer Immunotherapy Market 
06/05Eisai and Biogen's elenbecestat shows encouraging action in mid-stage Alzheim.. 
06/05MINING ASCO 2018'S GOLD, PART 11 : The Pains In The Neck 
06/01MINING ASCO 2018'S GOLD, PART 8 : Angiogenesis Taking Back Control Of Liver Canc.. 
Financials ( JPY)
Sales 2019 625 B
EBIT 2019 85 000 M
Net income 2019 52 714 M
Finance 2019 91 406 M
Yield 2019 1,84%
P/E ratio 2019 42,24
P/E ratio 2020 44,20
EV / Sales 2019 3,74x
EV / Sales 2020 3,73x
Capitalization 2 429 B
Chart EISAI CO., LTD
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | 4523 | JP3160400002 | 4-Traders
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 7 591  JPY
Spread / Average Target -7,1%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD25.73%21 948
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
MERCK AND COMPANY8.46%164 082